ArticleInternational journal of general medicine2025
Elevated Serum Fibulin-5 Levels Correlate with Coronary Artery Disease Progression.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibulin-5 (FBLN5) as a context-dependent pan-cancer regulator: integrated multi-omics analysis reveals dual roles in tumor progression and therapeutic resistance.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess the association between serum fibulin-5 levels and the progression of coronary artery disease (CAD) and its potential role as a diagnostic biomarker. Methods: This study was conducted by the Department of Cardiology at Shanghai Pudong Hospital, enrolling 186 patients diagnosed with CAD and 150 healthy controls. Clinical and biochemical parameters were compared between the groups using Student's Results: Compared to healthy individuals, patients with CAD exhibited significantly higher levels of body mass index (BMI), systolic blood pressure (SBP), fasting blood glucose (FBG), white blood cell (WBC) count, high-sensitivity C-reactive protein (hs-CRP), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), intima-media thickness (IMT), brachial-ankle pulse wave velocity (baPWV), and fibulin-5, along with reduced flow-mediated dilation (FMD) and high-density lipoprotein cholesterol (HDL-C) (all P<0.05). Patients with CAD involving >2 vessels showed significantly elevated SBP, hs-CRP, TG, TC, LDL-C, IMT, baPWV, and fibulin-5, and lower HDL-C and FMD than those with CAD involving ≤2 vessels (P < 0.05). ELISA results demonstrated significantly increased fibulin-5 levels in patients with CAD, with the highest levels in the >2 vessels group. ROC analysis identified a fibulin-5 cutoff value of 64.2 ng/mL, achieving 93% sensitivity and 72% specificity (AUC = 0.950) for differentiating CAD progression from healthy controls. Fibulin-5 levels were positively correlated with age, hs-CRP, TC, LDL-C, IMT, and baPWV, and negatively correlated with FMD. Multivariate logistic regression identified SBP, IMT, baPWV, and fibulin-5 as independent risk factors for CAD involving >2 vessels (P < 0.05). Conclusion: Serum fibulin-5 levels were significantly elevated in patients with CAD involving >2 vessels compared to healthy subjects and were positively correlated with disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.